Lenox Wealth Management Inc. bought a new stake in shares of Icon Plc (NASDAQ:ICLR) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 6,726 shares of the medical research company’s stock, valued at approximately $658,000.

Several other large investors also recently added to or reduced their stakes in the company. Shine Investment Advisory Services Inc. bought a new stake in shares of Icon Plc during the 2nd quarter worth $103,000. Acrospire Investment Management LLC lifted its position in shares of Icon Plc by 20.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Icon Plc by 20.7% during the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after buying an additional 217 shares during the last quarter. US Bancorp DE lifted its position in shares of Icon Plc by 15.0% during the 1st quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after buying an additional 251 shares during the last quarter. Finally, Huntington National Bank lifted its position in shares of Icon Plc by 5.0% during the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after buying an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Several analysts recently weighed in on ICLR shares. Zacks Investment Research downgraded Icon Plc from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. ValuEngine upgraded Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, September 1st. Jefferies Group LLC upgraded Icon Plc from a “hold” rating to a “buy” rating and increased their target price for the company from $86.00 to $117.00 in a research report on Thursday, June 29th. Robert W. Baird reiterated a “buy” rating and issued a $123.00 target price on shares of Icon Plc in a research report on Thursday. Finally, BidaskClub upgraded Icon Plc from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Icon Plc has an average rating of “Buy” and a consensus target price of $117.33.

Icon Plc (NASDAQ:ICLR) traded down 1.06% during midday trading on Friday, reaching $113.63. The company had a trading volume of 294,869 shares. Icon Plc has a one year low of $73.76 and a one year high of $117.53. The company has a 50-day moving average price of $113.04 and a 200-day moving average price of $98.07. The stock has a market capitalization of $6.14 billion, a price-to-earnings ratio of 23.05 and a beta of 0.59.

Icon Plc (NASDAQ:ICLR) last posted its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.01. Icon Plc had a net margin of 15.97% and a return on equity of 28.72%. The business had revenue of $431.00 million during the quarter, compared to the consensus estimate of $430.68 million. During the same period in the previous year, the firm posted $1.14 earnings per share. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts expect that Icon Plc will post $5.32 earnings per share for the current year.

WARNING: This story was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at http://www.mareainformativa.com/lenox-wealth-management-inc-buys-new-stake-in-icon-plc-iclr/117991/.

Icon Plc Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Institutional Ownership by Quarter for Icon Plc (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.